HAWKEYE BIO
Earlier diagnosis. Higher survival rates. Hawkeye is a new medical technology company focused on lung cancer.
CALIFORNIA, USA
More about Hawkeye Bio
NJF Capital presents Hawkeye Bio.
Lung cancer is the leading cause of cancer deaths worldwide, it usually starts growing very deep in the lung and without symptoms. Today lung cancer is often diagnosed late as the current screening method underperforms compared to other major cancers.
Hawkeye is the solution for identifying lung cancer patients earlier so they can benefit from a wider range of treatment options with better chances of success. Hawkeye’s 19 blood serum biomarkers provide a highly accurate, sensitive and specific readout for the presence of lung cancer, and is specially tuned for early stage disease. The test is designed to be 100% safe and cost-effective at any scale.
Hawkeye has confirmed its excellent performance in various clinical validations and has launched a global, multi-site clinical trial in the US, Europe and China in support of local regulatory approval and commercialization.
With Hawkeye, there will soon be a day when lung cancer can be detected so early that the five-year-survival rate will increase to nearly 100%.